Rank |
Status |
Study |
1 |
Recruiting
|
The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma
Condition: |
Asthma |
Interventions: |
Drug: Simvastatin; Drug: B1-6-12 |
Outcome Measures: |
Sputum eosinophils; Phosphorylated p38 MAPK in sputum cells |
|
2 |
Recruiting
|
Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Condition: |
Prostate Carcinoma |
Interventions: |
Drug: Metformin; Drug: Simvastatin |
Outcome Measures: |
Efficacy, as measured by an improvement in PSA doubling time (PSADT) between baseline and 6 months, of the combination of metformin plus Simvastatin in patients with recurrent prostate cancer following definitive treatment.; Time to protocol-specified event for men treated with the combination of metformin plus Simvastatin.; Pattern of change in log PSA levels and PSA velocity over time during treatment with metformin plus Simvastatin.; Associations between changes in metabolic parameters (fasting glucose/insulin/lipid panel/leptin/adiponectin and others) with the pattern of change in log PSA levels. |
|
3 |
Unknown †
|
Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer
Condition: |
Colorectal Cancer |
Intervention: |
Drug: Simvastatin |
Outcome Measure: |
Progression free survival |
|
4 |
Recruiting
|
Safety of Simvastatin in LAM and TSC
Conditions: |
Lymphangioleiomyomatosis; Tuberous Sclerosis Complex |
Intervention: |
Drug: Simvastatin |
Outcome Measures: |
Safety of Simvastatin in the treatment of LAM-S and LAM-TS patients on a stable (for at least 3 months) dose of sirolimus or everolimus.; FEV1, FVC, DLCO, VEGF-D, and QOL; signs of clinical benefit. |
|
5 |
Not yet recruiting
|
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Conditions: |
Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer |
Interventions: |
Drug: Simvastatin; Drug: Doxorubicin/cyclophosphamide |
Outcome Measures: |
Change in echocardiographic Global Longitudinal Strain (GLS); Number of participants with adverse events as a measure of safety and tolerability; Recurrence free survival (RFS) with concurrent Simvastatin |
|
6 |
Recruiting
|
Stroke Treatment With Acute Reperfusion and Simvastatin
Condition: |
Stroke, Acute |
Intervention: |
Drug: Simvastatin |
Outcome Measures: |
The primary outcome of this study is to determine whether Simvastatin treatment started within the first 12 hours from stroke onset improves neurological and functional outcomes, evaluated at seventh day/discharge or at the third month.; The secondary outcome of this study is to demonstrate that Simvastatin is safe and not associated with higher rates of hemorrhagic transformation in patients who receive thrombolysis. |
|
7 |
Recruiting
|
Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome
Conditions: |
Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Hypertriglyceridemia |
Interventions: |
Drug: Fenofibrate; Drug: Simvastatin |
Outcome Measures: |
Percentage change from baseline in triglycerides (TG) at week 12; Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 12; Percentage changes from baseline in apoB/apoA1 ratio at week 12; Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 12; Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 12; Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 12; Percentage changes from baseline in uric acid at week 12; Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 52; Percentage changes from baseline in apoB/apoA1 ratio at week 52; Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 52; Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 52; Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 52; Percentage changes from baseline in uric acid at week 52 |
|
8 |
Recruiting
|
Efficacy Study of Simvastatin to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment
Condition: |
Rhinosinusitis |
Intervention: |
Drug: Simvastatin |
Outcome Measures: |
Sino-Nasal symptomatology; Bacterial culture; Assessemt of liver and kidney functions; RNA measurement of inflammatory biomarkers; Sinus-Specific Quality of Life (22 questions Sino-nasal outcome test; SNOT-22); Aspect of sinus mucosa aspect assessed by sinus endoscopy |
|
9 |
Unknown †
|
Simvatstatin Used to Treat Pulmonary Hypertension
Condition: |
Hypertension, Pulmonary |
Intervention: |
Drug: Simvastatin |
Outcome Measures: |
the Simvastatin can alleviate pulmonary hypertension; pulmonary pressure; Simvastatin can highten the perioperative and long term survaval rate and the living quality |
|
10 |
Recruiting
|
Effects of Simvastatin on Biomarkers
Condition: |
Alzheimer's Disease |
Interventions: |
Drug: Simvastatin; Drug: Placebo |
Outcome Measures: |
Cerebral Spinal Fluid Biomarker measurements; Measures of inflammation or oxidative stress in cerebral spinal fluid. |
|
11 |
Recruiting
|
Simvastatin Addition for Patients With Recent-onset Schizophrenia
Conditions: |
Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychosis NOS |
Interventions: |
Drug: Simvastatin; Drug: Placebo |
Outcome Measures: |
Change in Positive And Negative Syndrome Scale (PANSS) total score; Change in PANSS positive, negative and general psychopathology scale scores; Change in Global Assessment of functioning scale (GAF) score; Change in cognitive functioning; Presence and severity of metabolic syndrome; Change in presence and severity of movement disorders using validated scales |
|
12 |
Unknown †
|
Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)
Conditions: |
Dyslipidemia; Atherosclerosis |
Interventions: |
Drug: Simvastatin; Drug: Nicotinic Acid |
Outcome Measures: |
change of carotid and femoral IMT from baseline to 6 and 12 months follow up and occurrence of major adverse cardiovascular events (MACE); changes of grey scale median (GSM) score from baseline to follow-up, and changes of serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides and lipoprotein (a). |
|
13 |
Not yet recruiting
|
The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia
Condition: |
Choroideremia |
Intervention: |
Drug: Simvastatin |
Outcome Measures: |
Full-field scotopic threshold; Microperimetry, OCT, fundus autofluorescence, ERG, VA |
|
14 |
Recruiting
|
Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Condition: |
Sickle Cell Disease |
Intervention: |
Drug: Simvastatin |
Outcome Measures: |
Vaso-occlusive pain events; Correlation of plasma biomarkers with clinical measures of vaso-occlusive pain; Clinical safety of Simvastatin |
|
15 |
Recruiting
|
Simvastatin Augmentation of Lithium Treatment in Bipolar Depression
Condition: |
Bipolar Disorder |
Interventions: |
Drug: Simvastatin; Drug: Placebo |
Outcome Measure: |
Change in MADRS (4 weeks) |
|
16 |
Recruiting
|
Simvastatin for mTBI
Condition: |
TBI-Traumatic Brain Injury |
Interventions: |
Drug: Simvastatin; Drug: placebo |
Outcome Measures: |
cerebrospinal fluid (CSF) tau concentration; Concentration of cerebrospinal fluid (CSF) Brain-derived neurotrophic factor (BDNF) |
|
17 |
Unknown †
|
Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.
Conditions: |
Diabetes Mellitus; Hypertension |
Interventions: |
Drug: atrorvastatin 10mg; Drug: Simvastatin 40mg |
Outcome Measures: |
Reduction in oxLDL levels; Reduction in plasma malondialdehydes and urine isoprostanes; Reduction in plasma endothelial function parameters such as soluble Vascular Adhesion Molecule (sVCAM) and von Willebrand factor |
|
18 |
Unknown †
|
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
Conditions: |
Cystic Fibrosis; Anti Inflammatory Non-Steroidal; Neutrophils |
Interventions: |
Drug: Pioglitazone; Drug: Simvastatin; Drug: Ibuprofen |
Outcome Measure: |
Neutrophil delivery to the oral mucosa using a noninvasive mouth wash technique |
|
19 |
Recruiting
|
Simvastatin Effect on Radiation Therapy of Brain Metastases
Condition: |
Brain Metastases |
Interventions: |
Drug: Simvastatin in addition to radiation therapy; Radiation: radiation therapy |
Outcome Measures: |
a- Response rate; progression free and overall survival; adverse effects |
|
20 |
Recruiting
|
Sarilumab Effect on the Pharmacokinetics of Simvastatin
Condition: |
Rheumatoid Arthritis |
Interventions: |
Drug: sarilumab SAR153191 (REGN88); Drug: Simvastatin |
Outcome Measures: |
Assessment of PK parameters - area under curve from zero time until the last measurable concentration (AUClast) and AUC for Simvastatin; Assessment of PK parameters - maximum concentration (Cmax), time to maximum concentration (tmax), and terminal half-life associated with the terminal slope (t1/2z) for Simvastatin; Assessment of PK parameters - Cmax, AUClast, AUC, tmax, t1/2z for Simvastatin acid; Number of participants with adverse events |
|